In vitro interactions between anidulafungin and nonsteroidal anti-inflammatory drugs on biofilms of Candida spp. |
| |
| Institution: | 1. Department of Pharmacy—Drug Sciences, University of Bari, ‘Aldo Moro’, Bari, Italy;2. Department of Biomedical Sciences and Human Oncology, Hygiene Section, University of Bari, ‘Aldo Moro’, Bari, Italy;1. Istituto di Biochimica delle Proteine – CNR, Via P. Castellino 111, 80131 Napoli, Italy;2. Università degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy;3. Department of Chemistry, College of Science, King Saud University, PO Box 2455, Riyadh 11451, Saudi Arabia;4. Università degli Studi di Firenze, Polo Scientifico, Dipartimento NEIROFABA;Sezione di Scienze Farmaceutiche e Nutraceutiche, Via Ugo Schiff 6, 50019 Sesto Fiorentino (Firenze), Italy;1. Universidade Federal de Santa Maria, Departamento de Química, Camobi, Santa Maria, RS, Brazil;2. Universidade Federal de Santa Maria, Departamento de Ciências do Solo, Camobi, Santa Maria, RS, Brazil;3. Universidade Federal de Santa Catarina, Departamento de Química, Trindade, Santa Catarina, SC, Brazil;1. Department of Radiation Oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China;2. Department of Pathology & Pathophysiology of Zhejiang University, School of Medicine, Hangzhou, China;1. Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, 27100 Pavia, Italy;2. Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK;3. Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore 560012, India;4. Departamento de Microbiología, Facultad de Medicina, and BIFI, Universidad de Zaragoza, and IIS-Aragón, 50009 Zaragoza, Spain;5. CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain;6. Fundación ARAID, Zaragoza, Spain;7. Department of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská dolina, Ilkovi?ova 6, 84215, Bratislava, Slovakia;8. Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA;9. Department of Chemistry, University of Cambridge, Lensfield Rd, Cambridge, CB2 1EW, UK;10. Univ Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, 1 rue du Professeur Calmette, 59000 Lille, France;11. Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ 07103, USA;12. Department of Pharmacology, Physiology, and Neuroscience, Rutgers University – New Jersey Medical School, Newark, NJ, 07103, USA;13. Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560064, India;14. Collaborative Drug Discovery, 1633 Bayshore Highway, Suite 342, Burlingame, CA 94403, USA |
| |
| Abstract: | Candida spp. are responsible for many biomaterial-related infections; they give rise to infective pathologies typically associated with biofilm formation. We recently reported that the echinocandin anidulafungin (ANF) showed a strong in vitro activity against both planktonic and biofilms cells. Herein, we report the antifungal activities of ANF alone and in association with some non-steroidal anti-inflammatory drugs (NSAIDs) against nine Candida strain biofilms: four Candida albicans, two Candida glabrata and three Candida guilliermondii. The activity of ANF was assessed using an in vitro microbiological model relevant for clinical practice. ANF proved oneself to be active against biofilms cells, and a clear-cut synergism was found against Candida species biofilms when ANF was used in combination with three NSAIDs: aspirin, diclofenac, ibuprofen. The positive synergism against Candida spp. of ANF in association with aspirin or the other NSAIDs proved to be a very effective antifungal treatment (FICI <0.5). These results may provide the starting point for new combination therapies of ANF with NSAIDs against Candida biofilm pathologies. |
| |
| Keywords: | Biofilm Non-steroidal anti-inflammatory drugs (NSAIDs) Anidulafungin XTT Synergism |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
